| Product Unit Size | Cost | Quantity | Stock |
|---|
AZD-7762 is a selective inhibitor of checkpoint kinase (CHK) 1 and CHK2. It enhances sensitivity of urothelial carcinoma cells to gemcitabine through the inhibition of DNA repair checkpoints. It also works with gemcitabine to suppress the growth of KRAS-driven LKB1-deficient lung adenocarcinomas.
| Cas No. | 860352-01-8 |
|---|---|
| Purity | ≥98% |
| Formula | C17H19FN4O2S |
| Formula Wt. | 362.42 |
| IUPAC Name | 3-(Carbamoylamino)-5-(3-fluorophenyl)-N-[(3S)-3-piperidinyl]-2-thiophenecarboxamide |
| Synonym | AZD 7762, AZD7762 |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Isono M., Hoffmann M., et al. Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine. J Exp Clin Cancer Res. 36(1):1 (2017). PMID: 28049532.
Liu Y., Li Y., et al. Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma. Cancer Res. 77(18):5068-76 (2017). PMID: 28754670.